Is Puma Biotechnology Stock a Good Investment?
Puma Biotechnology Investment Advice | PBYI |
- Examine Puma Biotechnology's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Puma Biotechnology's leadership team and their track record. Good management can help Puma Biotechnology navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Puma Biotechnology's business and its evolving consumer preferences.
- Compare Puma Biotechnology's performance and market position to its competitors. Analyze how Puma Biotechnology is positioned in terms of product offerings, innovation, and market share.
- Check if Puma Biotechnology pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Puma Biotechnology's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Puma Biotechnology stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Puma Biotechnology is a good investment.
Sell | Buy |
Strong Sell
Market Performance | OK | Details | |
Volatility | Very risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Puma Biotechnology Stock
Researching Puma Biotechnology's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 15.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.89. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Puma Biotechnology has Price/Earnings To Growth (PEG) ratio of 0.03. The entity had not issued any dividends in recent years.
To determine if Puma Biotechnology is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Puma Biotechnology's research are outlined below:
| Puma Biotechnology had very high historical volatility over the last 90 days | |
| About 59.0% of the company shares are owned by institutional investors | |
| Latest headline from globenewswire.com: Crinetics Pharmaceuticals Announces March 2025 Inducement Grants UnderNasdaq Listing Rule 5635 |
Puma Biotechnology uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Puma Biotechnology. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Puma Biotechnology's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Puma Biotechnology's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 174.13 M.Puma Biotechnology's profitablity analysis
The company has Profit Margin (PM) of 0.13 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.23 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.23.Determining Puma Biotechnology's profitability involves analyzing its financial statements and using various financial metrics to determine if Puma Biotechnology is a good buy. For example, gross profit margin measures Puma Biotechnology's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Puma Biotechnology's profitability and make more informed investment decisions.
Basic technical analysis of Puma Stock
As of the 24th of March, Puma Biotechnology holds the Semi Deviation of 2.95, coefficient of variation of 1023.7, and Risk Adjusted Performance of 0.0948. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Puma Biotechnology, as well as the relationship between them.Puma Biotechnology's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Puma Biotechnology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Puma Biotechnology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Puma Biotechnology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Puma Biotechnology's Outstanding Corporate Bonds
Puma Biotechnology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Puma Biotechnology uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Puma bonds can be classified according to their maturity, which is the date when Puma Biotechnology has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| PulteGroup 6 percent Corp BondUS745867AT82 | View | |
| PulteGroup 55 percent Corp BondUS745867AW12 | View | |
| PulteGroup 5 percent Corp BondUS745867AX94 | View | |
| PulteGroup 7875 percent Corp BondUS745867AM30 | View | |
| PulteGroup 6375 percent Corp BondUS745867AP60 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand Puma Biotechnology's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Puma Biotechnology's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0948 | |||
| Market Risk Adjusted Performance | (62.71) | |||
| Mean Deviation | 3.16 | |||
| Semi Deviation | 2.95 | |||
| Downside Deviation | 3.38 | |||
| Coefficient Of Variation | 1023.7 | |||
| Standard Deviation | 4.85 | |||
| Variance | 23.56 | |||
| Information Ratio | 0.1095 | |||
| Jensen Alpha | 0.4636 | |||
| Total Risk Alpha | 0.8327 | |||
| Sortino Ratio | 0.1573 | |||
| Treynor Ratio | (62.72) | |||
| Maximum Drawdown | 27.29 | |||
| Value At Risk | (5.45) | |||
| Potential Upside | 7.47 | |||
| Downside Variance | 11.42 | |||
| Semi Variance | 8.72 | |||
| Expected Short fall | (3.90) | |||
| Skewness | 2.1 | |||
| Kurtosis | 7.26 |
| Risk Adjusted Performance | 0.0948 | |||
| Market Risk Adjusted Performance | (62.71) | |||
| Mean Deviation | 3.16 | |||
| Semi Deviation | 2.95 | |||
| Downside Deviation | 3.38 | |||
| Coefficient Of Variation | 1023.7 | |||
| Standard Deviation | 4.85 | |||
| Variance | 23.56 | |||
| Information Ratio | 0.1095 | |||
| Jensen Alpha | 0.4636 | |||
| Total Risk Alpha | 0.8327 | |||
| Sortino Ratio | 0.1573 | |||
| Treynor Ratio | (62.72) | |||
| Maximum Drawdown | 27.29 | |||
| Value At Risk | (5.45) | |||
| Potential Upside | 7.47 | |||
| Downside Variance | 11.42 | |||
| Semi Variance | 8.72 | |||
| Expected Short fall | (3.90) | |||
| Skewness | 2.1 | |||
| Kurtosis | 7.26 |
Consider Puma Biotechnology's intraday indicators
Puma Biotechnology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Puma Biotechnology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Puma Biotechnology time-series forecasting models is one of many Puma Biotechnology's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Puma Biotechnology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Puma Stock media impact
Far too much social signal, news, headlines, and media speculation about Puma Biotechnology that are available to investors today. That information is available publicly through Puma media outlets and privately through word of mouth or via Puma internal channels. However, regardless of the origin, that massive amount of Puma data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Puma Biotechnology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Puma Biotechnology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Puma Biotechnology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Puma Biotechnology alpha.
Puma Biotechnology Corporate Management
| Jeffrey Ludwig | Chief Officer | Profile | |
| Alvin Pharmd | Chief Officer | Profile | |
| FRAPS BSc | Pharmacovigilance, Affairs | Profile | |
| Bo Chao | Senior Development | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Puma Biotechnology. If investors know Puma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Puma Biotechnology's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Puma Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Puma Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.